- COST-EFFECTIVENESS OF KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
- Clinical and Patient-Reported Outcomes in a Phase 3 Study of Axicabtagene Ciloleucel Versus Standard of Care in Elderly Patients With Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)
- Three-Year Follow-up of Outcomes With KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2
- Axicabtagene Ciloleucel in Combination With Rituximab for the Treatment of Refractory Large B‑Cell Lymphoma: Outcomes of the Phase 2 ZUMA‑14 Study
- Subgroup Analyses of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Adult Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in ZUMA-3
- Real-World Outcomes of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in the United States
- Association of Pretreatment Tumor Characteristics and Clinical Outcomes Following Second‑Line Axicabtagene Ciloleucel Versus Standard of Care in Patients With Relapsed/Refractory Large B‑Cell Lymphoma